CAS
PDLI

CTC Alternative Strategies’s PDL BioPharma, Inc. PDLI Stock Holding History

CTC Alternative Strategies’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-12,000
Closed -$92.6K – 245
2013
Q2 		$92.6K Buy
+12,000
New +$93.6K 0.03% 168

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

CTC Alternative Strategies's PDLI Position: Q3 2013 in Review

CTC Alternative Strategies sold out of PDL BioPharma, Inc. (PDLI) in Q3 2013, closing a stake of 12,000 shares — an estimated $92.6K sold.

CTC Alternative Strategies first reported a position in PDLI in Q2 2013 and held it in 1 quarter. The position peaked at $92.6K in Q2 2013. 212 funds tracked by Wall St. Rank hold PDLI as of Q3 2013.

  • CTC Alternative Strategies reported no remaining PDL BioPharma, Inc. position as of Q3 2013 after selling out during the quarter.
  • CTC Alternative Strategies sold 12,000 PDL BioPharma, Inc. shares in Q3 2013, an estimated $92.6K.
  • CTC Alternative Strategies first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 1 quarter.
  • CTC Alternative Strategies's PDL BioPharma, Inc. position peaked at $92.6K in Q2 2013.
  • 212 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2013.

Based on CTC Alternative Strategies's 13F filing for Q3 2013, filed 31 Oct 2013.